<DOC>
	<DOCNO>NCT01963260</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability single rise dos MK-8723 healthy adult participant adult participant chronic immune thrombocytopenia purpura ( ITP ) ass pharmacodynamics MK-8723 participant ITP . The primary hypothesis true placebo-adjusted platelet response rate MK-8723 adult patient chronic ITP &gt; 50 % .</brief_summary>
	<brief_title>Single Rising Dose Study MK-8723 Healthy Participants Participants With Immune Thrombocytopenia Purpura ( MK-8723-001 )</brief_title>
	<detailed_description>In Part 1 trial , safety pharmacokinetics MK-8723 evaluate healthy participant . In Part 2 trial , safety , pharmacokinetics , pharmacodynamics evaluate among participant ITP . In Part 1 , dose escalation occur 5 serial panel participant ; participant receive single intravenous ( IV ) dose MK-8723 ( placebo ) . In Part 2 , dose escalation occur 3 serial panel participant ITP ; participant receive single IV dose MK-8723 ( placebo ) , safety tolerability correspond dose show Part 1 . Amendment 3 specify re-enrollment procedure eligible participant Part 2 participate one dosing panel .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<criteria>Inclusion Criteria ( Part 1 ) : Female participant must nonpregnant , nonbreast feeding , nonchildbearing potential Has Body Mass Index ( BMI ) &lt; =32 kg/m^2 Has body weight &gt; = 50 kg &lt; = 100 kg Has judge good health base medical history , physical examination , vital sign measurement , electrocardiogram ( ECG ) , laboratory safety test Nonsmoker use nicotine nicotinecontaining product least 3 month Inclusion Criteria ( Part 2 ) : Has diagnose ITP least 3 month prior Female ITP participant must nonpregnant , nonbreast feeding , either 1 ) nonchildbearing potential 2 ) must serum beta human chorionic gonadotropin ( HCG ) level consistent nonpregnant state , agree use acceptable contraception pretrial period 84 day postdose Has BMI &lt; =36 kg/m^2 Has judge good health , ITP diagnosis , base medical history , physical examination , vital sign measurement , ECG , laboratory safety test Exclusion Criteria ( Part 1 ) : Has history clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary , major neurological abnormality diseases Has history cancer ( malignancy ) Has history significant multiple and/or severe allergy anaphylactic reaction significant intolerability prescription nonprescription drug food Is positive hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) Has major surgery donate lose 1 unit blood 4 week prior Has participate another investigational trial within 4 week ( 12 week biologics ) Has receive live virus vaccination within 42 day plan receive participate trial Is unable refrain anticipates use medication , include prescription nonprescription drug herbal remedy 2 week prior duration trial Consumes great 3 glass alcoholic beverage per day Consumes great 6 serving caffeinecontaining beverage per day Is currently regular user illicit drug history drug and/or alcohol abuse within 3 month Has history ITP autoimmune disease Has active infection clinically significant Exclusion Criteria ( Part 2 ) : Has comorbid significant hematological immunological disorder Has history significant multiple and/or severe allergy anaphylactic reaction significant intolerability prescription nonprescription drug food Is positive hepatitis B surface antigen , hepatitis C antibody , HIV Has major surgery donate lose 1 unit blood within 4 week Has participate another investigational trial within 4 week ( 12 week biologics ) , exclude prior participation current study Has history ITP unresponsive intravenous immunoglobulin ( IVIG ) Has systemic corticosteroid use within 1 month ( exception stable low dose oral corticosteroid ) Has systemic IVIG systemic immunomodulatory therapy , exclude MK8723 administration current study , within 3 month Has receive thrombopoietin receptor antagonist within 3 month Is unable refrain use thrombopoietin receptor agonist and/or systemic immune modulatory medication throughout study Has receive live virus vaccine within 42 day prior plan receive trial Consumes great 3 alcoholic beverage per day Consumes great 6 serving caffeinecontaining beverage per day Is currently regular user illicit drug history drug and/or alcohol abuse within 3 month Has clinical evidence bleed coagulopathy include petechial rash , easy bruising , excessive gingival bleed routine dental hygiene Has active infection clinically significant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>